Colloidal bismuth subcitrate impedes proton entry intoHelicobacter pyloriand increases the efficacy of growth-dependent antibiotics
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Colloidal bismuth subcitrate impedes proton entry intoHelicobacter pyloriand increases the efficacy of growth-dependent antibiotics
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 42, Issue 7, Pages 922-933
Publisher
Wiley
Online
2015-08-04
DOI
10.1111/apt.13346
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection
- (2015) Jyh-Chin Yang et al. Clinical Gastroenterology and Hepatology
- Helicobacter pylori
- (2014) Peter Malfertheiner et al. CURRENT OPINION IN GASTROENTEROLOGY
- Factors Affecting First-Line Triple Therapy of Helicobacter pylori Including CYP2C19 Genotype and Antibiotic Resistance
- (2014) Ju Yup Lee et al. DIGESTIVE DISEASES AND SCIENCES
- Efficacy of Bismuth-Containing Quadruple Therapies for Clarithromycin-, Metronidazole-, and Fluoroquinolone-Resistant Helicobacter pylori Infections in a Prospective Study
- (2013) Xiao Liang et al. Clinical Gastroenterology and Hepatology
- Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype
- (2012) M. Sugimoto et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The effects of varying acidity onHelicobacter pylorigrowth and the bactericidal efficacy of ampicillin
- (2012) E. A. Marcus et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report
- (2012) Peter Malfertheiner et al. GUT
- Role of the Helicobacter pylori Sensor Kinase ArsS in Protein Trafficking and Acid Acclimation
- (2012) E. A. Marcus et al. JOURNAL OF BACTERIOLOGY
- The actions of bismuth in the treatment of Helicobacter pylori infections: an update
- (2012) Ruiguang Ge et al. Metallomics
- Primer3—new capabilities and interfaces
- (2012) Andreas Untergasser et al. NUCLEIC ACIDS RESEARCH
- Inhibition of fumarase by bismuth(III): implications for the tricarboxylic acid cycle as a potential target of bismuth drugs in Helicobacter pylori
- (2011) Zhuo Chen et al. BIOMETALS
- Tracking Bismuth Antiulcer Drug Uptake in Single Helicobacter pylori Cells
- (2011) Cheuk-Nam Tsang et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial
- (2011) Peter Malfertheiner et al. LANCET
- Role of Omeprazole Dosage and Cytochrome P450 2C19 Genotype in Patients Receiving Omeprazole-Amoxicillin Dual Therapy forHelicobacter pyloriEradication
- (2011) Jyh-Chin Yang et al. PHARMACOTHERAPY
- Helicobacter pylori treatment in the era of increasing antibiotic resistance
- (2010) D. Y. Graham et al. GUT
- Green bismuth
- (2010) Ram Mohan Nature Chemistry
- Empiric Quadruple vs. Triple Therapy for Primary Treatment of Helicobacter pylori Infection: Systematic Review and Meta-Analysis of Efficacy and Tolerability
- (2009) Jay Luther et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Cytoplasmic Histidine Kinase (HP0244)-Regulated Assembly of Urease with UreI, a Channel for Urea and Its Metabolites, CO2, NH3, and NH4+, Is Necessary for Acid Survival of Helicobacter pylori
- (2009) D. R. Scott et al. JOURNAL OF BACTERIOLOGY
- ¿Son más eficaces dosis más elevadas de inhibidores de la bomba de protones para el tratamiento de la infección por Helicobacter pylori?
- (2008) Albert Villoria Gastroenterologia y Hepatologia
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More